Trial record 2 of 5 for:    STELARA Crohn's

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

This study is currently recruiting participants.
Verified April 2014 by Janssen Research & Development, LLC
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC
ClinicalTrials.gov Identifier:
NCT01369342
First received: June 7, 2011
Last updated: April 8, 2014
Last verified: April 2014
  Purpose

This study (UNITI-2) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to a placebo over 8 weeks in patients with moderately to severely active Crohn's disease.


Condition Intervention Phase
Crohn's Disease
Inflammatory Bowel Disease
IBD
Colitis
Drug: Group 3: ustekinumab approximately 6 mg/kg
Drug: Group 1: Placebo
Drug: Group 2 ustekinumab 130 mg
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)

Resource links provided by NLM:


Further study details as provided by Janssen Research & Development, LLC:

Primary Outcome Measures:
  • Clinical Response [ Time Frame: Week 6 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinical remission [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
  • Clinical improvement/response [ Time Frame: Study visits through Week 8 ] [ Designated as safety issue: No ]

Estimated Enrollment: 612
Study Start Date: July 2011
Estimated Study Completion Date: August 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 001
Group 1: Placebo Form=solution for injection route=intravenous use in a single dose.
Drug: Group 1: Placebo
Form=solution for injection, route=intravenous use, in a single dose.
Experimental: 002
Group 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
Drug: Group 2 ustekinumab 130 mg
Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
Experimental: 003
Group 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg) 390 mg (weight > 55 kg and <= 85 kg) and 520 mg (weight > 85 kg).
Drug: Group 3: ustekinumab approximately 6 mg/kg
Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg), 390 mg (weight > 55 kg and <= 85 kg), and 520 mg (weight > 85 kg).

Detailed Description:

This study (CNTO1275CRD3002 or "UNITI-2") examines ustekinumab (an antibody medication that inhibits the inflammatory proteins IL-12 and IL-23) versus a placebo (otherwise identical except without the ustekinumab antibody) given intravenously (by an IV) in adults with moderately to severely active Crohn's disease. Ustekinumab (also known as Stelara) is approved as a treatment for the skin condition of moderate to severe plaque-type psoriasis, but this study will examine if ustekinumab can provide benefit in Crohn's disease and also assess for any risks or side effects. Both the positive and negative outcomes of IV placebo versus two different doses of IV ustekinumab will be tracked and compared over eight weeks, in approximately 612 patients who have previously failed or were intolerant to corticosteroids or immunomodulators (methotrexate, azathioprine, or 6-mercaptopurine) or are dependent on corticosteroid medications. Patients enrolling in this study will be assigned to one of the 3 treatment groups by chance (randomly, like rolling dice), and all will receive a single IV administration of study agent at the first study visit (after the screening period), and then will be asked to return for 3 additional visits through Week 8. Patients who complete this study through the Week 8 visit and remain eligible can enter the maintenance study (CNTO1275CRD3003 or "IM-UNITI"), where they will receive additional study agent, including the administration of ustekinumab in patients who receive placebo in this study and have not had improvement in their Crohn's disease. Patients who do not enter the CNTO1275CRD3003 study will have a final safety follow-up visit approximately 20 weeks after they received study agent when they entered into this study at the Week 0 visit. .All patients will receive a single intravenous (IV) administration of study drug (placebo or ustekinumab) at the start of the study.There are 3 treatment groups in this study: Group 1: Placebo; Group 2: ustekinumab 130 mg, Group 3: weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg), 390 mg (weight > 55 kg and <= 85 kg), and 520 mg (weight > 85 kg).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have Crohn's disease of at least 3 months' duration with colitis, ileitis, or ileocolitis, confirmed at some time in the past by radiography, histology, or endoscopy
  • Have active Crohn's disease, defined as a baseline Crohn Disease Activity Index (CDAI) score of >= 220 and <= 450, with confirmation of active inflammation
  • Has failed conventional therapy as demonstrated by having received corticosteroids and/or immunomodulators(ie, AZA, MTX, or 6-MP) at adequate therapeutic doses OR Have a history of failure to respond to or tolerate an adequate course of corticosteroids and/or immunomodulators (ie, AZA, MTX, or 6-MP) at adequate therapeutic doses OR Is corticosteroid dependent or has had a history of corticosteroid dependency AND Has not previously demonstrated failure of or intolerance to 1 or more TNF-antagonist therapies (ie, infliximab, adalimumab, or certolizumab pegol) per study criteria
  • Have screening laboratory test results within protocol-specified parameters

Exclusion Criteria:

  • Patients who have had any kind of bowel resection within 6 months
  • Are pregnant or planning pregnancy (both men and women) while enrolled in the study or for 20 weeks after receiving study agent
  • Patients who have received infliximab, adalimumab or certolizumab pegol < = 8 weeks before the first administration of study drug
  • Patients with certain complications of Crohn's disease that would make it hard to assess response to study drug
  • Patients with a history of or ongoing chronic or recurrent infectious disease
  • Patients who have previously received a biologic agent targeting IL-12 or IL-23, including but not limited to ustekinumab (CNTO 1275) or briakinumab (ABT-874)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01369342

Contacts
Contact: Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions: JNJ.CT@sylogent.com

  Hide Study Locations
Locations
United States, Alabama
Withdrawn
Birmingham, Alabama, United States
United States, Arizona
Recruiting
Tucson, Arizona, United States
United States, Arkansas
Completed
Little Rock, Arkansas, United States
United States, California
Recruiting
La Jolla, California, United States
Recruiting
Los Angeles, California, United States
Withdrawn
Orange, California, United States
Recruiting
San Diego, California, United States
Withdrawn
San Francisco, California, United States
Recruiting
Santa Monica, California, United States
Completed
Torrance, California, United States
United States, Colorado
Recruiting
Lone Tree, Colorado, United States
United States, Florida
Recruiting
Boca Raton, Florida, United States
Recruiting
Gainesville, Florida, United States
Recruiting
Jacksonville, Florida, United States
Recruiting
Largo, Florida, United States
Recruiting
Miami, Florida, United States
Recruiting
Naples, Florida, United States
Recruiting
Port Orange, Florida, United States
Recruiting
Winter Park, Florida, United States
United States, Georgia
Recruiting
Athens, Georgia, United States
Recruiting
Atlanta, Georgia, United States
Recruiting
Decatur, Georgia, United States
Recruiting
Macon, Georgia, United States
United States, Idaho
Recruiting
Idaho Falls, Idaho, United States
United States, Illinois
Recruiting
Chicago, Illinois, United States
United States, Iowa
Recruiting
Clive, Iowa, United States
Withdrawn
Iowa City, Iowa, United States
United States, Kansas
Recruiting
Pratt, Kansas, United States
Recruiting
Topeka, Kansas, United States
United States, Kentucky
Recruiting
Crestview Hills, Kentucky, United States
Completed
Lexington, Kentucky, United States
Recruiting
Louisville, Kentucky, United States
United States, Louisiana
Recruiting
Baton Rouge, Louisiana, United States
Recruiting
Houma, Louisiana, United States
Recruiting
New Orleans, Louisiana, United States
United States, Maryland
Recruiting
Chevy Chase, Maryland, United States
Recruiting
Towson, Maryland, United States
United States, Massachusetts
Completed
Boston, Massachusetts, United States
Recruiting
Worcester, Massachusetts, United States
United States, Michigan
Recruiting
Ann Arbor, Michigan, United States
Recruiting
Chesterfield, Michigan, United States
Recruiting
Novi, Michigan, United States
Recruiting
Troy, Michigan, United States
Recruiting
Ypsilanti, Michigan, United States
United States, Minnesota
Recruiting
Rochester, Minnesota, United States
United States, Mississippi
Recruiting
Ocean Springs, Mississippi, United States
United States, Missouri
Recruiting
Columbia, Missouri, United States
Completed
Kansas City, Missouri, United States
Recruiting
Lees Summit, Missouri, United States
Recruiting
Mexico, Missouri, United States
United States, Nevada
Recruiting
Las Vegas, Nevada, United States
United States, New Jersey
Recruiting
Egg Harbor, New Jersey, United States
Recruiting
Marlton, New Jersey, United States
Completed
Morristown, New Jersey, United States
United States, New York
Withdrawn
Brooklyn, New York, United States
Recruiting
Great Neck, New York, United States
Recruiting
New York, New York, United States
Completed
New York, New York, United States
Recruiting
Poughkeepsie, New York, United States
United States, North Carolina
Recruiting
Chapel Hill, North Carolina, United States
Completed
Charlotte, North Carolina, United States
Recruiting
Raleigh, North Carolina, United States
United States, Ohio
Completed
Beavercreek, Ohio, United States
Recruiting
Cincinnati, Ohio, United States
Recruiting
Columbus, Ohio, United States
Recruiting
Mentor, Ohio, United States
United States, Oklahoma
Recruiting
Norman, Oklahoma, United States
Recruiting
Oklahoma City, Oklahoma, United States
Completed
Tulsa, Oklahoma, United States
United States, Oregon
Completed
Bend, Oregon, United States
Recruiting
Portland, Oregon, United States
United States, Pennsylvania
Completed
Malvern, Pennsylvania, United States
Recruiting
Philadelphia, Pennsylvania, United States
Withdrawn
Pittsburgh, Pennsylvania, United States
United States, South Carolina
Recruiting
Columbia, South Carolina, United States
Recruiting
North Charleston, South Carolina, United States
United States, Tennessee
Completed
Germantown, Tennessee, United States
Withdrawn
Germantown, Tennessee, United States
Recruiting
Nashville, Tennessee, United States
United States, Texas
Recruiting
Austin, Texas, United States
Recruiting
Grapevine, Texas, United States
Completed
Houston, Texas, United States
Recruiting
Houston, Texas, United States
Recruiting
Tyler, Texas, United States
United States, Utah
Recruiting
Salt Lake City, Utah, United States
United States, Virginia
Recruiting
Charlottesville, Virginia, United States
Recruiting
Chesapeake, Virginia, United States
Completed
Virginia Beach, Virginia, United States
United States, Washington
Completed
Bellevue, Washington, United States
Recruiting
Seattle, Washington, United States
United States, Wisconsin
Completed
Madison, Wisconsin, United States
Recruiting
Madison, Wisconsin, United States
Australia
Recruiting
Adelaide, Australia
Completed
Cairns, Australia
Recruiting
Central Queensland M C, Australia
Recruiting
Concord, Australia
Completed
Fremantle, Australia
Recruiting
Garran, Australia
Recruiting
Liverpool, Australia
Completed
Malvern, Australia
Recruiting
Parkville, Australia
Belgium
Completed
Brussel, Belgium
Recruiting
Brussel, Belgium
Recruiting
Leuven, Belgium
Brazil
Recruiting
Goiás, Brazil
Recruiting
Porto Alegre, Brazil
Recruiting
Rio De Janeiro, Brazil
Withdrawn
Santo André, Brazil
Recruiting
Sao Paulo, Brazil
Completed
São Paulo, Brazil
Recruiting
São Paulo, Brazil
Bulgaria
Recruiting
Pleven, Bulgaria
Recruiting
Rousse, Bulgaria
Recruiting
Sofia, Bulgaria
Withdrawn
Sofia, Bulgaria
Recruiting
Varna, Bulgaria
Canada, Alberta
Recruiting
Calgary, Alberta, Canada
Recruiting
Edmonton, Alberta, Canada
Canada, British Columbia
Recruiting
Vancouver, British Columbia, Canada
Withdrawn
Vancouver, British Columbia, Canada
Canada, Manitoba
Recruiting
Brandon, Manitoba, Canada
Canada, New Brunswick
Withdrawn
Saint John, New Brunswick, Canada
Canada, Ontario
Recruiting
Kingston, Ontario, Canada
Recruiting
London, Ontario, Canada
Recruiting
Toronto, Ontario, Canada
Canada, Quebec
Recruiting
Montreal, Quebec, Canada
Withdrawn
Montreal N/A, Quebec, Canada
Canada, Saskatchewan
Completed
Saskatoon, Saskatchewan, Canada
Canada
Withdrawn
Toronto, Canada
Recruiting
Winnipeg N/A, Canada
Croatia
Recruiting
Avenija Gojka Suska 6, Croatia
Completed
Osijek, Croatia
Recruiting
Rijeka, Croatia
Recruiting
Zagreb, Croatia
Completed
Zagreb, Croatia
France
Recruiting
Amiens Cedex 1, France
Recruiting
Bordeaux, France
Completed
Caen Cedex 9, France
Completed
Paris, France
Recruiting
Paris Cedex 18, France
Recruiting
Rouen, France
Recruiting
Vandoeuvre Les Nancy, France
Germany
Completed
Berlin, Germany
Recruiting
Berlin, Germany
Completed
Bochum, Germany
Withdrawn
Essen, Germany
Recruiting
Frankfurt, Germany
Recruiting
Halle, Germany
Completed
Hamburg, Germany
Recruiting
Hannover, Germany
Recruiting
Haßloch, Germany
Recruiting
Heidelberg, Germany
Recruiting
Kiel, Germany
Completed
Lÿneburg, Germany
Recruiting
Mannheim, Germany
Recruiting
Minden, Germany
Recruiting
München, Germany
Recruiting
Münster, Germany
Withdrawn
Oberhausen, Germany
Recruiting
Regensburg, Germany
Recruiting
Stade, Germany
Completed
Ulm, Germany
Hungary
Recruiting
Budapest, Hungary
Recruiting
Budapest N/A, Hungary
Recruiting
Békéscsaba, Hungary
Recruiting
Debrecen, Hungary
Completed
Gyula, Hungary
Recruiting
Mosonmagyaróvár, Hungary
Recruiting
Pecs, Hungary
Recruiting
Szekesfehervar, Hungary
Recruiting
Szekszard, Hungary
Iceland
Recruiting
Reykjavik, Iceland
Israel
Recruiting
Beer Yaakov, Israel
Recruiting
Haifa, Israel
Recruiting
Jerusalem, Israel
Recruiting
Kfar Saba, Israel
Recruiting
Petah Tikva, Israel
Recruiting
Rehovot, Israel
Recruiting
Tel Aviv, Israel
Japan
Recruiting
Chikushino, Japan
Recruiting
Hachioji, Japan
Recruiting
Hamamatsu, Japan
Recruiting
Hirosaki, Japan
Recruiting
Hiroshima, Japan
Recruiting
Kagoshima, Japan
Recruiting
Nishinomiya, Japan
Recruiting
Ohtsu, Japan
Recruiting
Oita, Japan
Recruiting
Osaka, Japan
Recruiting
Sakura, Japan
Recruiting
Sapporo, Japan
Recruiting
Sendai, Japan
Recruiting
Shinjuku, Japan
Recruiting
Suita-Shi, Japan
Recruiting
Tokyo, Japan
Recruiting
Tsu, Japan
Recruiting
Uruma, Japan
Recruiting
Yokkaichi, Japan
Recruiting
Yokohama, Japan
Recruiting
Yokosuka, Japan
Korea, Republic of
Recruiting
Daegu, Korea, Republic of
Recruiting
Gyeonggi-Do, Korea, Republic of
Recruiting
Seoul, Korea, Republic of
Netherlands
Recruiting
Amsterdam, Netherlands
Recruiting
Amsterdam Zuidoost, Netherlands
Completed
Maastricht, Netherlands
Recruiting
Rotterdam, Netherlands
New Zealand
Recruiting
Auckland, New Zealand
Withdrawn
Auckland, New Zealand
Recruiting
Christchurch, New Zealand
Recruiting
Dunedin, New Zealand
Recruiting
Grafton, New Zealand
Recruiting
Hamilton, New Zealand
Recruiting
Hastings, New Zealand
Recruiting
Plenty, New Zealand
Completed
Wellington, New Zealand
Poland
Completed
Bydgoszcz, Poland
Recruiting
Elblag, Poland
Withdrawn
Krakow, Poland
Recruiting
Krakow, Poland
Recruiting
Lodz, Poland
Withdrawn
Poznan, Poland
Recruiting
Warszawa, Poland
Withdrawn
Wroclaw, Poland
Russian Federation
Withdrawn
Kaluga, Russian Federation
Recruiting
Moscow, Russian Federation
Withdrawn
Nizhny Novgorod, Russian Federation
Recruiting
Novosibirsk, Russian Federation
Withdrawn
Saint Petersburg, Russian Federation
Serbia
Completed
Belgrade, Serbia
Recruiting
Belgrade, Serbia
Recruiting
Beograd, Serbia
South Africa
Withdrawn
Benoni, South Africa
Recruiting
Cape Town, South Africa
Completed
Cape Town, South Africa
Completed
Durban, South Africa
Withdrawn
Johannesburg, South Africa
Withdrawn
Johannesburg N/A, South Africa
Recruiting
Pretoria, South Africa
Spain
Recruiting
Madrid, Spain
Recruiting
Sabadell, Spain
Recruiting
Santiago De Compostela, Spain
Withdrawn
Sevilla, Spain
United Kingdom
Recruiting
Birmingham, United Kingdom
Completed
Brighton, United Kingdom
Recruiting
Bristol, United Kingdom
Recruiting
Cambridge, United Kingdom
Completed
Gloucester, United Kingdom
Completed
Harrow, United Kingdom
Recruiting
Liverpool, United Kingdom
Recruiting
London, United Kingdom
Completed
London, United Kingdom
Recruiting
Manchester, United Kingdom
Recruiting
Norwich, United Kingdom
Recruiting
Nottinghamshirecc, United Kingdom
Recruiting
Oxford, United Kingdom
Recruiting
Shrewsbury, United Kingdom
Withdrawn
South Shields, United Kingdom
Recruiting
Southampton, United Kingdom
Sponsors and Collaborators
Janssen Research & Development, LLC
Investigators
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
  More Information

Additional Information:
No publications provided

Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT01369342     History of Changes
Other Study ID Numbers: CR018418, CNTO1275CRD3002, 2010-022759-42
Study First Received: June 7, 2011
Last Updated: April 8, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Janssen Research & Development, LLC:
ustekinumab
moderately to severely active Crohn's Disease
Stelara
IBD
colitis
crohn
UNITI
Crohn's

Additional relevant MeSH terms:
Crohn Disease
Colitis
Inflammatory Bowel Diseases
Intestinal Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 17, 2014